肝硬化门静脉血栓的抗凝与TIPS个体化治疗:前瞻性观察研究
该前瞻性观察研究纳入396例肝硬化合并良性门静脉血栓患者,按肝病分期及血栓程度采用等待观察、抗凝、TIPS或TIPS联合抗凝的个体化方案。中位随访31.7个月,81.3%实现再通,TIPS与抗凝均与更高再通概率相关,长期用依诺肝素或利伐沙班(而非华法林)与更低再血栓风险和更好生存相关且不增加出血。
要点
- 个体化治疗算法在肝硬化门静脉血栓中再通率高、门脉高压并发症及不良事件发生率低
- TIPS与抗凝均与更高再通概率相关,需按肝病分期和血栓程度选择
- 长期依诺肝素或利伐沙班较华法林再血栓风险更低、生存更好且不增加出血
核心结论
- 肝硬化门静脉血栓患者采用个体化治疗算法可获得高概率再通,门脉高压并发症及不良事件发生率低。
研究设计与样本
- 2014年2月至2018年6月单中心前瞻性纳入396例肝硬化合并非恶性门静脉血栓的连续患者。
- 48例(12.1%)未治疗,63例(15.9%)抗凝,88例(22.2%)TIPS,197例(49.8%)TIPS联合术后抗凝。
- 治疗选择主要取决于肝病分期(有无症状性门脉高压)及血栓程度和范围。
主要发现
- 中位随访31.7个月,312例(81.3%)实现部分(25例)或完全(287例)再通,9例(3.1%)再血栓。
- 64例(16.2%)发生大出血,其中抗凝相关出血7例(1.8%);88例(22.2%)发生显性肝性脑病;100例(25.3%)死亡。
- 多变量竞争风险回归中,TIPS与抗凝均与更高再通概率相关。
- 长期使用依诺肝素或利伐沙班(而非华法林)与再血栓风险降低和生存改善相关,且不增加出血风险。
- 完全性肠系膜上静脉血栓与更低再通率、更高大出血风险和不良预后相关。
临床怎么用
- 对肝硬化门静脉血栓可按肝病分期及血栓程度和范围选择等待观察、抗凝、TIPS或TIPS联合抗凝的个体化方案。
- 长期抗凝可优先考虑依诺肝素或利伐沙班而非华法林,以降低再血栓风险并改善生存且不增加出血。
- 完全性肠系膜上静脉血栓患者再通率低、大出血风险高、预后差,需加强监测与个体化决策。
局限性
- 为单中心前瞻性观察研究,非随机对照,治疗选择受肝病分期和血栓特征影响可能存在混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Current guidelines recommend anticoagulation as the mainstay of portal vein thrombosis (PVT) treatment in cirrhosis. However, because of the heterogeneity of PVT, anticoagulation alone does not always achieve satisfactory results. This study aimed to prospectively evaluate an individualized management algorithm using a wait-and-see strategy (i.e., no treatment), anticoagulation, and transjugular intrahepatic portosystemic shunt (TIPS) to treat PVT in cirrhosis. METHODS: Between February 2014 and June 2018, 396 consecutive patients with cirrhosis with nonmalignant PVT were prospectively included in a tertiary care center, of which 48 patients (12.1%) were untreated, 63 patients (15.9%) underwent anticoagulation, 88 patients (22.2%) underwent TIPS, and 197 patients (49.8%) received TIPS plus post-TIPS anticoagulation. The decision of treatment option mainly depends on the stage of liver disease (symptomatic portal hypertension or not) and degree and extension of thrombus. RESULTS: During a median 31.7 months of follow-up period, 312 patients (81.3%) achieved partial (n = 25) or complete (n = 287) recanalization, with 9 (3.1%) having rethrombosis, 64 patients (16.2%) developed major bleeding (anticoagulation-related bleeding in 7 [1.8%]), 88 patients (22.2%) developed overt hepatic encephalopathy, and 100 patients (25.3%) died. In multivariate competing risk regression models, TIPS and anticoagulation were associated with a higher probability of recanalization. Long-term anticoagulation using enoxaparin or rivaroxaban rather than warfarin was associated with a decreased risk of rethrombosis and an improved survival, without increasing the risk of bleeding. However, the presence of complete superior mesenteric vein thrombosis was associated with a lower recanalization rate, increased risk of major bleeding, and poor prognosis. DISCUSSION: In patients with cirrhosis with PVT, the individualized treatment algorithm achieves a high-probability recanalization, with low rates of portal hypertensive complications and adverse events.
引用
- Lv Y, Bai W, Li K, et al. Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study. Am J Gastroenterol. 2021. PMID: 33630766. doi:10.14309/ajg.0000000000001194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。